Method for predicting the response to HER2-directed therapy

Details for Australian Patent Application No. 2003302821 (hide)

International Classifications

Event Publications

29 July 2004 Complete Application Filed

Priority application(s): 60/432,942 11.12.02 US

5 August 2004 Application Open to Public Inspection

Published as AU-B-2003302821

7 May 2009 Application Accepted

Published as AU-B-2003302821

10 September 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

17 September 2009 Section 223 Application Allowed

Ventana Medical Systems, Inc.; Cell Signaling Technology, Inc. The time in which to pay the acceptance fee has been extended to 07 Sep 2009. Address for service in Australia - Houlihan2 Level 1 70 Doncaster Road Balwyn North VIC 3104 2005

24 September 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.